Melatonin

Melatonin, circadian biology and aging.

Melatonin is a hormone produced mainly at night and is best known for signaling biological darkness and helping regulate the sleep-wake cycle. It is synthesized in the pineal gland from tryptophan under control of the brain's master circadian clock, the suprachiasmatic nucleus. Melatonin rises in the evening, helps coordinate nighttime physiology and falls toward morning. Nighttime secretion often declines with age, which is one reason melatonin has attracted interest in sleep disorders and aging research.

Its strongest established role is as a chronobiotic: a signal that can shift or reinforce circadian timing. As people age, daily rhythms often become less distinct, with earlier waking, fragmented sleep and weaker day-night physiological differences. Appropriately timed exogenous melatonin can help realign circadian rhythms and improve sleep timing or subjective sleep quality in some older adults. Timing matters because taking melatonin at the wrong phase of the circadian cycle can reduce benefit or shift rhythms in an unintended direction.

Melatonin is also studied as an antioxidant. It can directly interact with reactive oxygen and nitrogen species and can influence endogenous antioxidant enzymes. Unlike many antioxidants, melatonin distributes through both aqueous and lipid environments and crosses the blood-brain barrier. These properties have generated substantial mechanistic interest, but antioxidant activity in cells does not by itself establish a clinical anti-aging effect.

Mitochondria are a major focus of this research. Experimental work suggests that melatonin can accumulate within mitochondria, reduce excessive reactive-species formation, support respiratory efficiency and stabilize mitochondrial membranes under stress. Some studies also suggest local mitochondrial melatonin synthesis. These findings provide a plausible link between circadian signaling, energy metabolism and cellular stress resistance, but most of this evidence remains preclinical.

Melatonin also interacts with immune and inflammatory pathways. Aging is often accompanied by chronic low-grade inflammation and reduced immune responsiveness. Cell and animal studies show that melatonin can modulate inflammatory cytokines such as IL-6 and TNF-α and influence innate and adaptive immune responses. Small human studies have reported changes in inflammatory markers, but the clinical importance and optimal dosing remain uncertain.

Longevity evidence. Several animal experiments have reported longer average or maximum lifespan after chronic melatonin administration, with some rodent studies describing increases on the order of 10–20% and some fruit-fly studies reporting larger effects. Other experiments found no lifespan benefit, and outcomes varied by species, dose, timing and genetic background. A few high-dose animal studies have also raised concerns about adverse effects. Taken together, the preclinical literature supports biological effects on aging pathways but does not justify describing melatonin as a proven longevity drug.

Brain aging. Melatonin levels are often reduced in older adults and can be particularly disrupted in neurodegenerative disease. People with Alzheimer's disease frequently experience sleep fragmentation and evening agitation, or “sundowning.” Clinical studies suggest that melatonin can improve sleep-related symptoms in some patients with cognitive impairment or dementia. Experimental Alzheimer's models also report effects on oxidative stress, beta-amyloid and tau-related pathology, but evidence that melatonin slows human neurodegeneration remains insufficient.

In Parkinson's disease, melatonin is used mainly to address sleep and circadian disturbances. Cell and animal studies suggest possible protection of dopaminergic neurons from oxidative stress, while ischemia and stroke models report reductions in neuronal injury. These neuroprotective findings are promising but should be distinguished from demonstrated disease modification in humans.

Cardiovascular physiology. Melatonin participates in the normal night-time fall in blood pressure and may influence vascular tone and autonomic balance. Some clinical studies in people with hypertension suggest that evening melatonin can modestly improve nocturnal blood-pressure dipping. Experimental studies also report endothelial and cardioprotective effects during ischemic stress. These findings are relevant to cardiovascular aging, although melatonin is not a substitute for established hypertension or cardiovascular therapy.

Metabolism and meal timing. Melatonin helps synchronize metabolism with the day-night cycle. High nighttime melatonin is physiologically associated with fasting and reduced insulin secretion. Eating late at night while melatonin is elevated can therefore worsen glucose tolerance in susceptible individuals. Genetic variants in melatonin receptors have also been associated with diabetes risk. Animal studies often show improvements in insulin sensitivity and adipose inflammation with melatonin, whereas human metabolic trials remain smaller and less consistent.

Cancer research. Epidemiological studies have linked chronic nighttime light exposure and shift work with altered cancer risk, prompting hypotheses about circadian disruption and melatonin suppression. Laboratory experiments show antiproliferative, pro-apoptotic and anti-angiogenic effects of melatonin in several tumor models. Small adjunctive oncology trials have also been conducted. These results do not establish melatonin as an anticancer treatment, and it should not replace evidence-based oncologic therapy.

Response to supplementation varies considerably. Genetics, liver metabolism, endogenous melatonin production, age, light exposure, dose and timing can all alter the duration and magnitude of effect. Someone with a weak endogenous nighttime signal may respond differently from someone whose circadian melatonin rhythm is already robust.

Melatonin is generally well tolerated at commonly used doses, but adverse effects can include morning drowsiness, headache, dizziness, nausea and vivid dreams. It can increase sedation when combined with alcohol, antihistamines, benzodiazepines or other sedating agents. Long-term safety data are less extensive than short-term data, particularly in pregnancy, childhood and some autoimmune or endocrine conditions.

Future work is focused on better matching dose, formulation and timing to the therapeutic goal; using controlled-release formulations to mimic physiological secretion; combining melatonin with light therapy and other circadian interventions; and testing whether long-term treatment affects cognition, frailty or other healthspan outcomes.

In summary, melatonin is an important circadian hormone with biologically plausible antioxidant, mitochondrial, immune and neuroprotective effects. Human evidence is strongest for circadian timing and certain sleep-related uses. Evidence that melatonin meaningfully slows human aging, prevents neurodegenerative disease or extends lifespan remains unproven, so those possibilities should be treated as active research questions rather than established benefits.